Sandy Spring Bank’s Fate Therapeutics FATE Stock Holding History

Sandy Spring Bank’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-50	Closed	-$175	–	1253
2024 Q3	$175	Buy	+50	New	+$195	﹤0.01%	1158

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sandy Spring Bank's FATE Position: Q4 2024 in Review

Sandy Spring Bank sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 50 shares — an estimated $175 sold.

Sandy Spring Bank first reported a position in FATE in Q3 2024 and held it in 1 quarter. The position peaked at $175 in Q3 2024. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

Sandy Spring Bank reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
Sandy Spring Bank sold 50 Fate Therapeutics shares in Q4 2024, an estimated $175.
Sandy Spring Bank first reported a position in Fate Therapeutics in Q3 2024 and held it in 1 quarter.
Sandy Spring Bank's Fate Therapeutics position peaked at $175 in Q3 2024.
159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Sandy Spring Bank's 13F filing for Q4 2024, filed 11 Feb 2025.